Clinical Trial Update: Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD. [Phase 4]

View source ↗

Summary

A Phase 4 safety, tolerability, and pharmacokinetics study of extended-release methylphenidate in 4- to 5-year-olds with ADHD has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Methylphenidate HCl ERCT (methylphenidate extended-release)

Snippet

Sponsor: Pfizer | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Status: WITHDRAWN